



Studio > Drug Repurposing Analysis

Execution

Events

Timeline

- Research Coordinator** 4.50s (+8.51s) + 1 task
 - quick_research_overview
 - Started
 - LLM call
 - Search the internet with Serper
 - LLM call
 - Completed
- Clinical Trials Research Agent** 13.06s (+24.61s) + 1 task
 - clinical_trials_analysis_task
 - LLM call
 - Started
 - Search the internet with Serper
 - LLM call
 - Search the internet with Serper

Event details

Details Raw Data

microsoft_word_create_text_document

12/10/2025, 7:15:16 AM

Input

```
{
  "file_name": "Metformin_Drug_Repurposing_Report.docx",
  "content": [
    {"text": "Metformin Drug Repurposing Summary Report", "style": "Title"}, {"text": "Executive Summary", "style": "Heading1"}, {"text": "Metformin, primarily known as an oral hypoglycemic agent for type 2 diabetes, has shown promising potential in repurposing for various other indications. This report synthesizes key findings from recent clinical trials, elucidates the mechanism of action, and highlights strategic repurposing opportunities.", "style": "Normal"}, {"text": "Clinical Trial Overview", "style": "Heading1"}, {"text": "1. Metformin in Alzheimer's Disease\nPrimary Outcome: Evaluate the efficacy of metformin in slowing cognitive decline as measured by cognitive assessments.\nKey Safety Findings: Preliminary results showed that metformin was safe and well-tolerated in the study population, with no significant adverse effects reported.", "style": "Normal"}, {"text": "2. Efficacy and safety of metformin plus low-dose temozolomide in patients with glioblastoma", "style": "Heading2"}, {"text": "Indication Tested: Glioblastoma\nPrimary Outcome: Metformin significantly improved overall survival rates and progression-free survival compared to historical controls.\nKey Safety Findings: Metformin was generally well tolerated, with common side effects such as gastrointestinal disturbances; however, no severe adverse events were directly attributed to metformin.", "style": "Normal"}, {"text": "3. A randomized phase II/III study of paclitaxel/carboplatin/metformin for advanced endometrial cancer", "style": "Normal"}, {"text": "Indication Tested: Advanced endometrial cancer\nPrimary Outcome: The combination of metformin with paclitaxel/carboplatin showed no improvement in overall efficacy", "style": "Normal"}
  ]
}
```

Studio > Drug Repurposing Analysis

Visual Editor **Execution**

Events

Timeline

- Knowledge Extraction Agent** 37.66s (+9.29s) + 1 task
 - Started 0.00s
 - LLM call 1.5s + 1.54s
 - Search the internet with Serper 455ms + 1.97s
 - LLM call 7.4s + 9.31s
 - Completed 9.29s
- Report Aggregator Agent** 47.27s (+28.80s) + 1 task
 - Comprehensive Report Generation Task 28.80s + 47.27s
 - Started 0.00s
 - LLM call 1.6s + 1.65s
 - microsoft_word_get_documents 762ms + 2.42s
 - LLM call 1.1s + 3.59s
 - microsoft_word_get_documents 2.0s + 5.64s
 - LLM call 17.7s + 23.37s

Event details

Output

```
{
  "result": {
    "@odata.context": "https://graph.microsoft.com/v1.0/$metadata#users('bramhanichowdary2007%40gmail.com')/drive/root/$entity",
    "@odata.id": "https://graph.microsoft.com/v1.0/users('bramhanichowdary2007%40gmail.com')/drive/root"
  }
}
```